Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in POLE/POLD-mutated and non-MSI-H advanced solid tumors
NCT03810339Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in solid tumor, sponsored by Sun Yat-sen University. Started Jan 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03810339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810339.